Treating Hepatitis C Saves Lives and Money

Hepatitis C (HCV) is an infectious disease raging across the US, that can be cured in as little as eight weeks. Experts recommend treating HCV as early as possible to avoid long-term effects.¹ But the CDC estimates that four in ten people living with HCV do not know they have it.² While identifying and treating HCV comes with a cost.

The cost of not treating HCV is much greater and is borne by individuals; families; Medicaid; Medicare; and private insurance plans.

Because states and federal agencies lack funding for testing, surveillance, and treatment, too many people are not treated, leading to:

- Worse health outcomes
- Increased transmission and spread of HCV
- Additional costs to treat conditions caused by or exacerbated by long-term HCV³


Significant savings would be generated through increased investment in HCV outreach, screening, and treatment:

- Private Insurance: \$10-14 billion over 20 years⁴
- Medicare: \$4-12 billion over 20 years⁵
- Medicaid: \$3.8 billion over enrollees' lifetime⁶

ADDITIONAL COSTS AND HEALTH RISKS CREATED BY NOT TREATING HCV

Chronic Disease	Increased Likelihood	Annual Cost/Person
Liver Cancer	17.0x ⁷	\$ 60,863 ⁸
Liver Failure	6.6x ⁹	\$ 575,000 ¹⁰
Renal Failure	2.9x ⁹	\$ 76,059 ^{*11}
COPD	2.4x ⁹	\$ 9,800 **12
Mood & Anxiety Conditions	2.2x ⁹	\$ 6,475 ^{**13}
Rheumatoid Arthritis	2.0x 14	\$ 36,053 ¹⁵
Type 2 Diabetes	1.3x ⁹	\$ 9,601 ¹⁶
Asthma	1.3x ⁹	\$ 3,226 17

Not Treating HCV is Costly



Cost to cure based on publicly available data of the price paid by Department of Defense, Department of Veteran Affairs, Coast Guard, and the Bureau of Indian Affairs. Medicaid, Medicare, and private insurers can acquire even lower prices through discounts and rebates.

*Medicare's average per patient cost

**Includes extra medical costs for comorbidities exacerbated by the condition



FACT SHEET

¹ American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. 2020. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. https://www.hcvguidelines.org/

² Centers for Disease Control and Prevention. 2020. Vital Signs: Dramatic increases in hepatitis C. https://www.cdc.gov/hepatitis/hcv/vitalsigns/index.html

³ Center for Health Law and Policy Innovation of Harvard Law School. 2020. Hepatitis C: State of Medicaid Access. https://stateofhepc.org/

⁴ Moreno, Gigi et al. 2016. "Costs and Spillover Effects of Private Insurers' Coverage of Hepatitis C Treatment." *American Journal of Managed Care*. https://www.ajmc.com/view/costs-and-spillover-effects-of-private-insurers-coverage-of-hepatitis-c-treatment

⁵ Moreno, Gigi et al. 2016. "Costs and Spillover Effects of Private Insurers' Coverage of Hepatitis C Treatment." *American Journal of Managed Care*. https://www.ajmc.com/view/costs-and-spillover-effects-of-private-insurers-coverage-of-hepatitis-c-treatment

⁶ Younossi, Zobair et al. 2017. "Treating Medicaid Patients with Hepatitis C: Clinical and Economic Impact." *American Journal of Managed Care*. https://www.ajmc.com/view/treating-medicaid-patients-with-hepatitis-c-clinical-and-economic-impact

⁷ Lin, Ming et al. 2015. "Hepatitis C Virus-Associated Cancer." Annual Review of Pathology. https://www.annualreviews.org/doi/10.1146/annurev-pathol-012414-040323

⁸ Xu, Fujie et al. 2014. "Hospitalizations and Costs Associated With Hepatitis C And Advanced Liver Disease Continue To Increase." Health Affairs. https://www.healthaffairs.org/doi/10.1377/hlthaff.2014.0096

⁹ Cooper, Curtis et al. 2019. "HCV-Infected Individuals Have Higher Prevalence of Comorbidity and Multimorbidity: A Retrospective Cohort Study." *BMC Infectious Diseases*. https://doi.org/10.1186/s12879-019-4315-6

¹⁰ Disability Benefits Help. "Liver Disease and Social Security Disability." https://www.disability-benefits-help.org/disablingconditions/liver-disease-and-social-security-disability

¹¹ United States Renal Data System. 2020. "Healthcare Expenditures for Persons with ESRD." Annual Data Report. https://adr.usrds.org/2020/end-stage-renal-disease/9-healthcare-expenditures-for-persons-with-esrd

¹² Ford, Earl et al. 2015. "Total and State-Specific Medical and Absenteeism Costs of COPD Among Adults Aged ≥ 18 Years in the United States for 2010 and Projections Through 2020." *Chest.* https://doi.org/10.1378/chest.14-0972

¹³ Revicki, Dennis et al. 2012. "Humanistic and Economic Burden of Generalized Anxiety Disorder in North America and Europe." *Journal of Affective Disorders*. https://doi.org/10.1016/j.jad.2011.11.014

¹⁴ Fu-Hsiung Su et al. 2014. "Chronic Hepatitis C Virus Infection Is Associated with the Development of Rheumatoid Arthritis." *PLOS ONE*. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0113579

¹⁵ Hresko, Andrew et al. 2018. "Medical Care Costs Associated with Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-Analysis." *Arthritis Care & Research*. http://doi.org/10.1002/acr.23512

¹⁶ American Diabetes Association. 2018. The Cost of Diabetes. https://www.diabetes.org/resources/statistics/cost-diabetes

¹⁷ Tursynbeck, Nurmagambetov et al. 2018. "The Economic Burden of Asthma in the United States, 2008-2013." *Annual American Thoracic Society*. https://doi.org/10.1513/annalsats.201703-259oc

¹⁸ Barber, Melissa J. et al. 2020. "Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries." *Journal of Virus Eradication*. https://doi.org/10.1016/j.jve.2020.06.001

¹⁹ Razavi, Homie et al. 2013. "Chronic Hepatitis C Virus (HCV) Disease Burden Cost in the United States." Hepatology. https://doi.org/10.1002/hep.26218

